| ［1］ |
中国医师协会皮肤科医师分会皮肤美容亚专业委员会. 中国玫瑰痤疮诊疗专家共识（2016）［J］. 中华皮肤科杂志, 2017,50（3）:156⁃161. doi: 10.3760/cma.j.issn.0412⁃4030.2017.03.002.<br />
|
| ［2］ |
Two AM, Wu W, Gallo RL, et al. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea［J］. J Am Acad Dermatol, 2015,72（5）:761⁃770; quiz 771⁃772. doi: 10.1016/j.jaad. 2014.08.027.<br />
|
| ［3］ |
Del RJQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies［J］. Cutis, 2014,93（1）:18⁃28.<br />
|
| ［4］ |
Tüzün Y, Wolf R, Kutlubay Z, et al. Rosacea and rhinophyma［J］. Clin Dermatol, 2014,32（1）:35⁃46. doi: 10.1016/j.clindermatol. 2013. 05.024.<br />
|
| ［5］ |
van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for rosacea［J］. Cochrane Database Syst Rev, 2015,（4）:CD003262. doi: 10.1002/14651858.CD003262.pub5.<br />
|
| ［6］ |
Sobolewska B, Doycheva D, Deuter C, et al. Treatment of ocular rosacea with once⁃daily low⁃dose doxycycline［J］. Cornea, 2014,33（3）:257⁃260. doi: 10.1097/ICO.0000000000000051.<br />
|
| ［7］ |
Reinholz M, Tietze JK, Kilian K, et al. Rosacea ⁃ S1 guideline［J］. J Dtsch Dermatol Ges, 2013,11（8）:768⁃780. doi: 10. 1111/ddg. 12101.<br />
|
| ［8］ |
Abokwidir M, Feldman SR. Rosacea management［J］. Skin Appendage Disord, 2016,2（1⁃2）:26⁃34. doi: 10.1159/000446215.<br />
|
| ［9］ |
Akhyani M, Ehsani AH, Ghiasi M, et al. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial［J］. Int J Dermatol, 2008,47（3）:284⁃288. doi: 10.1111/j.1365⁃4632.2008.03445.x.<br />
|
| ［10］ |
Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR⁃2⁃mediated innate immune responses in acne patients［J］. J Invest Dermatol, 2012,132（9）:2198⁃2205. doi: 10.1038/jid.2012.111.<br />
|
| ［11］ |
Rademaker M. Very low⁃dose isotretinoin in mild to moderate papulopustular rosacea; a retrospective review of 52 patients［J］. Australas J Dermatol, 2018,59（1）:26⁃30. doi: 10.1111/ajd.12522.<br />
|
| ［12］ |
Gollnick H, Blume⁃Peytavi U, Szabó EL, et al. Systemic isotretinoin in the treatment of rosacea ⁃ doxycycline⁃ and placebo⁃controlled, randomized clinical study［J］. J Dtsch Dermatol Ges, 2010,8（7）:505⁃515. doi: 10.1111/j.1610⁃0387.2010.07345.x.<br />
|
| ［13］ |
Wee JS, Tan KB. Phymatous rosacea presenting with leonine facies and clinical response to isotretinoin［J］. Australas J Dermatol, 2017,58（1）:72⁃73. doi: 10.1111/ajd.12505.<br />
|
| ［14］ |
Hsu CC, Lee JY. Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea［J］. Arch Dermatol, 2011,147（11）:1258⁃1260. doi: 10.1001/archdermatol.2011.204.<br />
|
| ［15］ |
Layton A, Thiboutot D. Emerging therapies in rosacea［J］. J Am Acad Dermatol, 2013,69（6 Suppl 1）:S57⁃S65. doi: 10.1016/j.jaad. 2013.04.041.<br />
|
| ［16］ |
袁斌, 陈志健, 王炼. 硫酸羟氯喹联合0.1％他克莫司软膏治疗红斑毛细血管扩张型玫瑰痤疮疗效观察［J］. 临床合理用药杂志, 2016,9（31）:74⁃75. doi: 10.15887/j.cnki.13⁃1389/r.2016.31. 048.<br />
|
| ［17］ |
Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15 gel［J］. J Am Acad Dermatol, 2013,69（4）:570⁃577. doi: 10.1016/j.jaad.2013.05.019.<br />
|
| ［18］ |
Thiboutot DM, Fleischer AB, Del RJQ, et al. Azelaic acid 15 gel once daily versus twice daily in papulopustular rosacea［J］. J Drugs Dermatol, 2008,7（6）:541⁃546.<br />
|
| ［19］ |
Salem DA, El⁃Shazly A, Nabih N, et al. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin⁃metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum［J］. Int J Infect Dis, 2013,17（5）:e343⁃347. doi: 10.1016/j.ijid.2012.11.022.<br />
|
| ［20］ |
de Ménonville S T, Rosignoli C, Soares E, et al. Topical treatment of rosacea with ivermectin inhibits gene of cathelicidin innate immune mediators, LL⁃37 and KLK5, in reconstructed and ex vivo skin models［J］. Dermatol Ther （Heidelb）, 2017,7（2）:213⁃225. doi: 10.1007/s13555⁃017⁃0176⁃3.<br />
|
| ［21］ |
Siddiqui K, Stein GL, Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta⁃analysis［J］. Springerplus, 2016,5（1）:1151. doi: 10.1186/s40064⁃016⁃2819⁃8.<br />
|
| ［22］ |
Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea［J］. J Eur Acad Dermatol Venereol, 2009,23（2）:239⁃240. doi: 10.1111/j.1468⁃3083.2008.02822.x.<br />
|
| ［23］ |
El⁃Heis S, Buckley DA. Rosacea⁃like eruption due to topical pimecrolimus［J/OL］. Dermatol Online J, 2015,21（5）. pii: 13030/qt7kd1048m［2017⁃05⁃25］. https://cloudfront.escholarship.org/dist/prd/content/qt7kd1048m/qt7kd1048m.pdf?t=o41bak.<br />
|
| ［24］ |
Hu L, Alexander C, Velez NF, et al. Severe tacrolimus⁃induced granulomatous rosacea recalcitrant to oral tetracyclines［J］. J Drugs Dermatol, 2015,14（6）:628⁃630.<br />
|
| ［25］ |
Moore A, Kempers S, Murakawa G, et al. Long⁃term safety and efficacy of once⁃daily topical brimonidine tartrate gel 0.5 for the treatment of moderate to severe facial erythema of rosacea: results of a 1⁃year open⁃label study［J］. J Drugs Dermatol, 2014,13（1）:56⁃61.<br />
|
| ［26］ |
Jackson JM, Fowler J, Moore A, et al. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea［J］. J Drugs Dermatol, 2014,13（6）:699⁃704.<br />
|
| ［27］ |
Holmes AD, Waite KA, Chen MC, et al. Dermatological adverse events associated with topical brimonidine gel 0.33 in subjects with erythema of rosacea: a retrospective review of clinical studies［J］. J Clin Aesthet Dermatol, 2015,8（8）:29⁃35.<br />
|
| ［28］ |
Kassir R, Kolluru A, Kassir M. Intense pulsed light for the treatment of rosacea and telangiectasias［J］. J Cosmet Laser Ther, 2011,13（5）:216⁃222. doi: 10.3109/14764172.2011.613480.<br />
|
| ［29］ |
Liu J, Liu J, Ren Y, et al. Comparative efficacy of intense pulsed light for different erythema associated with rosacea［J］. J Cosmet Laser Ther, 2014,16（6）:324⁃327. doi: 10.3109/14764172.2014. 957218.<br />
|
| ［30］ |
Baek JO, Hur H, Ryu HR, et al. Treatment of erythemato⁃telangiectatic rosacea with the fractionation of high⁃fluence, long⁃pulsed 595⁃nm pulsed dye laser［J］. J Cosmet Dermatol, 2017,16（1）:12⁃14. doi: 10.1111/jocd.12284.<br />
|
| ［31］ |
Say EM, Okan G, Gökdemir G. Treatment outcomes of long⁃pulsed Nd: YAG laser for two different subtypes of rosacea［J］. J Clin Aesthet Dermatol, 2015,8（9）:16⁃20.<br />
|
| ［32］ |
Alam M, Voravutinon N, Warycha M, et al. Comparative effectiveness of nonpurpuragenic 595⁃nm pulsed dye laser and microsecond 1064⁃nm neodymium:yttrium⁃aluminum⁃garnet laser for treatment of diffuse facial erythema: a double⁃blind randomized controlled trial［J］. J Am Acad Dermatol, 2013,69（3）:438⁃443. doi: 10.1016/j.jaad.2013.04.015.<br />
|
| ［33］ |
Madan V, Ferguson JE, August PJ. Carbon dioxide laser treatment of rhinophyma: a review of 124 patients［J］. Br J Dermatol, 2009,161（4）:814⁃818. doi: 10.1111/j.1365⁃2133.2009.09317.x.<br />
|
| ［34］ |
Serowka KL, Saedi N, Dover JS, et al. Fractionated ablative carbon dioxide laser for the treatment of rhinophyma［J］. Lasers Surg Med, 2014,46（1）:8⁃12. doi: 10.1002/lsm.22184.<br />
|
| ［35］ |
吴晓瑾, 陈向东, 费烨, 等. 光动力疗法治疗酒渣鼻的疗效［J］.中华医学美学美容杂志, 2014,20（1）:36⁃39. doi: 10.3760/cma.j.issn.1671⁃0290.2014.01.010.<br />
|
| ［36］ |
刘伟, 袁丹, 王倩, 等. 利用光纤导入组织内光动力疗法治疗酒渣鼻15例疗效观察与分析［J］. 中国美容医学, 2015,24（19）:41⁃44.<br />
|
| ［37］ |
Friedmann DP, Goldman MP, Fabi SG, et al. Multiple sequential light and laser sources to activate aminolevulinic acid for rosacea［J］. J Cosmet Dermatol, 2016,15（4）:407⁃412. doi: 10.1111/jocd. 12231.<br />
|
| ［38］ |
Prado R, Funke A, Bingham J, et al. Treatment of severe rhino⁃phyma using scalpel excision and wire loop tip electrosurgery［J］. Dermatol Surg, 2013,39（5）:807⁃810. doi: 10.1111/dsu.12193.w.<br />
|
